GeoVax Labs has received a $1.9m award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, for the development of a clade C version of GeoVax's present clade B vaccine products.
Clade C vaccines are being developed to treat the HIV virus in the developing world.
GeoVax board chairman David Dodd said the company will continue to be grateful to the National Institutes of Health — National Institute of Allergy and Infectious Diseases for their continued support of company’s vaccine program.
”As HIV is a global disease, attention to the development of a clade C vaccine has always been a Company goal," Dodd added.
GeoVax president and CEO Robert McNally said, "Our clade B vaccines have shown excellent safety and reproducible immunogenicity during testing in Phase 1 and Phase 2a trials in North and South America."
The Company’s clade B vaccines address the HIV virus predominant in the developed world.